ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

New Drugs And Older Ones In New Uses Show Progress Against Several Cancers

April 25, 2008

Nelson Elected ACCC Veep

February 13, 1976

“Official Chronology” Of Gall/Montagnier Finding Agreed On; Royalties to Fund AIDS research

April 10, 1987

Governors Hear Pitch For State Cancer Control Increased Effort

August 3, 1979

Three Institutions In Texas To Form Center For Childhood Cancer Epidemiology Research.

February 2, 2001

FDA Invites Ad Hoc Consumer Reps To ODAC Meetings

February 17, 1995